CN109432118B - 白鹤藤碱在生物医药中的应用 - Google Patents
白鹤藤碱在生物医药中的应用 Download PDFInfo
- Publication number
- CN109432118B CN109432118B CN201811605346.9A CN201811605346A CN109432118B CN 109432118 B CN109432118 B CN 109432118B CN 201811605346 A CN201811605346 A CN 201811605346A CN 109432118 B CN109432118 B CN 109432118B
- Authority
- CN
- China
- Prior art keywords
- human
- cancer cells
- rhinacine
- medicine
- cell carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 13
- RXVGBQCEAQZMLW-UHFFFAOYSA-N alpha-solanine Natural products CC1CCC2C(C)C3C(CC4C5CC=C6CC(CCC6(C)C5CCC34C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C(O)C9O)N2C1 RXVGBQCEAQZMLW-UHFFFAOYSA-N 0.000 title abstract description 6
- ZGVSETXHNHBTRK-OTYSSXIJSA-N solanine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZGVSETXHNHBTRK-OTYSSXIJSA-N 0.000 title abstract description 6
- 229940031352 solanine Drugs 0.000 title abstract description 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims abstract description 12
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 26
- 230000005764 inhibitory process Effects 0.000 abstract description 15
- 206010005003 Bladder cancer Diseases 0.000 abstract description 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 11
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 7
- 206010006451 bronchitis Diseases 0.000 abstract description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 abstract description 3
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 240000002396 Rhinacanthus nasutus Species 0.000 abstract description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 3
- 230000009982 effect on human Effects 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract description 3
- 201000007270 liver cancer Diseases 0.000 abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 abstract description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 abstract description 3
- 201000011549 stomach cancer Diseases 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 206010006458 Bronchitis chronic Diseases 0.000 abstract description 2
- 201000004624 Dermatitis Diseases 0.000 abstract description 2
- 206010016654 Fibrosis Diseases 0.000 abstract description 2
- 206010017553 Furuncle Diseases 0.000 abstract description 2
- 206010030113 Oedema Diseases 0.000 abstract description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract description 2
- 208000010668 atopic eczema Diseases 0.000 abstract description 2
- 208000007451 chronic bronchitis Diseases 0.000 abstract description 2
- 230000007882 cirrhosis Effects 0.000 abstract description 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 208000004396 mastitis Diseases 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229930183854 Rhinacanthin Natural products 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000994304 Argyreia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了白鹤藤碱在生物医药中的应用。白鹤藤全草药用,其在广西贵港、玉林、防城港、武鸣等地有分布,中医用于治疗急慢性支气管炎、肺痨、肝硬化、肾炎水肿、疮疖、乳痈、皮肤湿疹、外伤出血等症。白鹤藤碱是分离自白鹤藤中的一种化学成分。本发明测试了白鹤藤碱对人肺腺癌细胞H2228、人膀胱癌细胞T24、人肝癌细胞SMMC‑7721、人乳腺癌细胞MCF‑7、人胃癌细胞MGC‑803、人口腔鳞状细胞癌Tca8113的增殖抑制活性,发现白鹤藤碱对人膀胱癌细胞T24、人口腔鳞状细胞癌Tca8113具有优异的抑制作用,对其他测试的肿瘤细胞抑制作用不明显,因此,白鹤藤碱可用于制备治疗膀胱癌或口腔鳞状细胞癌的药物。
Description
技术领域
本发明属于医药领域,涉及已知天然产物的新用途,具体涉及白鹤藤碱的新用途。
背景技术
白鹤藤Argyreia aceta全草药用,据《广西药用植物名录》记载,其在广西贵港、玉林、防城港、武鸣等地有分布,中医用于治疗急慢性支气管炎、肺痨、肝硬化、肾炎水肿、疮疖、乳痈、皮肤湿疹、外伤出血等症。白鹤藤碱是分离自白鹤藤中的一种化学成分(卢汝梅等,白鹤藤中的1个新生物碱,中草药第49卷第15期2018年8月)。
目前尚未见白鹤藤碱抗肿瘤活性的报道。
发明内容
本发明的目的在于提供一种白鹤藤碱的新用途。
实现本发明上述目的技术方案如下:
白鹤藤碱在制备治疗膀胱癌的药物中的应用。
一种治疗膀胱癌的药物制剂,以活性成分和药剂学上可以接受的辅料制成药剂学上可以接受的剂型,所述活性成分为白鹤藤碱。
进一步地,所述辅料为固体、半固体或液体辅料。
进一步地,所述剂型优选片剂、胶囊、注射剂。
白鹤藤碱在制备治疗口腔鳞状细胞癌的药物中的应用。
一种治疗口腔鳞状细胞癌的药物制剂,以活性成分和药剂学上可以接受的辅料制成药剂学上可以接受的剂型,所述活性成分为白鹤藤碱。
进一步地,所述辅料为固体、半固体或液体辅料。
进一步地,所述剂型优选片剂、胶囊、注射剂。
本发明的突出优点:
本发明测试了白鹤藤碱对人肺腺癌细胞H2228、人膀胱癌细胞T24、人肝癌细胞SMMC-7721、人乳腺癌细胞MCF-7、人胃癌细胞MGC-803、人口腔鳞状细胞癌Tca8113的增殖抑制活性,发现白鹤藤碱对人膀胱癌细胞T24、人口腔鳞状细胞癌Tca8113具有优异的抑制作用,对其他测试的肿瘤细胞抑制作用不明显,因此,白鹤藤碱可以用于制备治疗膀胱癌或口腔鳞状细胞癌的药物。
附图说明
图1为白鹤藤碱对各癌细胞增殖抑制的IC50值。
具体实施方式
下面就结合实施例具体介绍本发明的实质性内容,由于篇幅原因,实验过程的描述无法做到非常详细,凡是实验中未详细描述的部分均为本领域技术人员熟知的常规操作。
一、实验材料
人肺腺癌细胞H2228、人膀胱癌细胞T24、人肝癌细胞SMMC-7721、人乳腺癌细胞MCF-7、人胃癌细胞MGC-803、人口腔鳞状细胞癌Tca8113分别用含有10%胎牛血清的RPMI-1640培养基于37℃、5%CO2细胞培养箱中常规培养,实验选用对数生长期细胞。
白鹤藤碱自制,纯度>98%。
RPMI-1640培养基、胎牛血清购自Gibco。
二、实验方法
采用MTT法测试白鹤藤碱对各癌细胞的增殖抑制作用,根据白鹤藤碱对各癌细胞增殖抑制活性的IC50值评价其抗癌效果,具体步骤为:将各癌细胞接种到含有RPMI-1640+10%胎牛血清培养基的96孔板中,37℃、5%CO2条件培养24h,向培养板中加入培养基稀释的梯度浓度的白鹤藤碱及空白对照处理72h,再向每孔加入浓度为5mg/mL的MTT试剂20μL,继续培养4h,弃上清液,再向每孔加入150μLDMSO,振荡溶解,采用酶标仪测定570nm波长下的吸光度值(OD570),根据如下公式计算白鹤藤碱对各癌细胞抑制率,Graphpad拟合求得IC50值。
抑制率(%)=(空白对照组OD570-实验组OD570)/空白对照组OD570×100%
三、实验结果
白鹤藤碱对各癌细胞增殖抑制的IC50值如表1和图1所示。
表1白鹤藤碱对各癌细胞增殖抑制的IC50值
上述实验结果表明,白鹤藤碱对人膀胱癌细胞T24、人口腔鳞状细胞癌Tca8113具有优异的抑制作用,对其他测试的肿瘤细胞抑制作用不明显,因此,白鹤藤碱可以用于制备治疗膀胱癌或口腔鳞状细胞癌的药物。
上述实施例是对本发明实质性内容的体现,用于更好地解释本发明,但本领域技术人员应当知晓,不应将本发明的保护范围局限于上述具体的实施例。
Claims (1)
1.白鹤藤碱在制备治疗口腔鳞状细胞癌的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811605346.9A CN109432118B (zh) | 2018-12-26 | 2018-12-26 | 白鹤藤碱在生物医药中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811605346.9A CN109432118B (zh) | 2018-12-26 | 2018-12-26 | 白鹤藤碱在生物医药中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109432118A CN109432118A (zh) | 2019-03-08 |
CN109432118B true CN109432118B (zh) | 2020-12-01 |
Family
ID=65538232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811605346.9A Expired - Fee Related CN109432118B (zh) | 2018-12-26 | 2018-12-26 | 白鹤藤碱在生物医药中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109432118B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107513084A (zh) * | 2017-08-29 | 2017-12-26 | 广西中医药大学 | 白鹤藤碱及其提取方法及其用途 |
-
2018
- 2018-12-26 CN CN201811605346.9A patent/CN109432118B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107513084A (zh) * | 2017-08-29 | 2017-12-26 | 广西中医药大学 | 白鹤藤碱及其提取方法及其用途 |
Non-Patent Citations (1)
Title |
---|
白鹤藤中的1个新生物碱;卢汝梅等;《中草药》;20180831;第49卷(第15期);第3572-3575页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109432118A (zh) | 2019-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI421085B (zh) | 牛樟芝抗癌活性物質、製備方法及其用途 | |
CN109010618B (zh) | 一种具有抗肿瘤作用的中药组合物及制备方法和应用 | |
CN108912086B (zh) | 一种活性黄酮类化合物及其制备方法与应用 | |
CN102731276A (zh) | 具有抗肿瘤活性的二萜化合物及其制备方法与应用 | |
CN109432118B (zh) | 白鹤藤碱在生物医药中的应用 | |
CN109364092B (zh) | 一种白鹤藤碱的用途 | |
CN102267891B (zh) | 一种三萜化合物及其制备方法 | |
CN103893412B (zh) | 一种抗肿瘤裸花紫珠提取物及其制备方法和用途 | |
CN105399794A (zh) | 罗汉果三萜皂甙及其盐和其制备方法、应用及包含该罗汉果三萜皂甙及其盐的药物组合物 | |
CN102247357B (zh) | 紫玉盘内酰胺和马兜铃内酰胺bi在制备抗癌药物中的应用 | |
CN108796022B (zh) | 柴胡皂苷元a和d的制备方法及应用 | |
CN105801634B (zh) | 核桃青皮中一种直链醇苷化合物的制备方法和应用 | |
CN108836982A (zh) | 一种蟾皮有效部位及其制备方法 | |
CN103833823A (zh) | 二萜二聚体类化合物及其药物组合物和制备方法与应用 | |
CN106580937B (zh) | 月腺大戟素a的制备方法及其在制备乳腺癌药物中的应用 | |
CN110522776B (zh) | 一种黄槿中抗肿瘤有效部位的制备方法及应用 | |
CN103610682A (zh) | 3α-羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
CN102988525A (zh) | 山楂核中总木脂素的制备方法及新用途 | |
CN113214214A (zh) | 关苍术中一种新的萜类化合物的制备方法和应用 | |
JP2015515993A (ja) | ヒトシクロオキシゲナーゼ及びドキソルビシン又はドキソルビシン類を含有する医薬組成物、その調製方法及び多種薬物の製造における使用 | |
CN113801000A (zh) | 一种具有抗肿瘤活性的化合物及其制备方法和应用 | |
WO2020098329A1 (zh) | 牛樟芝萃取物、牛樟芝组合物的制备方法及医药组合物 | |
CN101062045B (zh) | 一类三萜皂苷化合物在制备肿瘤药物中的用途 | |
CN109498624B (zh) | 一种噻唑啉衍生物的抗癌医药用途 | |
CN109705183A (zh) | 臭七次生代谢物及其药物组合物与其制备方法和其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201111 Address after: 100162, No. 5 police road, Jinxing Town, Daxing District, Beijing, Xihongmen Applicant after: MAIDIHAI PHARMACEUTICAL Co.,Ltd. Address before: 211198 No. 18 Zhilan Road, Science Park, Jiangning District, Nanjing City, Jiangsu Province Applicant before: NANJING GAISIFU MEDICAL TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201201 |